Category: Cancer

Cancer

OGT Launches NGS Panel to Detect Residual Disease in Acute Myeloid Leukemia

The RNA-based panel detects leukemia-associated gene fusions at levels as low as 1% tumor cells, offering another approach to monitoring residual disease.

Medicover Genetics Launches Blood-Based MRD Test for Lung Cancer
Path Fertility Receives $2 Million NIH Grant to Develop Test for Male Infertility and Associated Cancer Risk
AI Model Uses Routine Pathology Slides to Predict Breast Cancer Recurrence Risk
Abbott Launches Whole-Genome Sequencing MRD Test Tracking Up to 5,000 Variants
Hologic to Acquire Reveal Genomics to Expand Breast Cancer Genomic Testing Portfolio
Labcorp and Waters Partner to Offer Extended-Genotype BD Onclarity HPV Assay Nationwide
Abbott Blood Test Improves Detection of Residual Colorectal Cancer After Surgery
Genomic Test Predicts Which Prostate Cancer Patients Benefit From Abiraterone Therapy
Biodesix Advances Tumor-Informed and Tumor-Naïve MRD Assays

Cancer

Quest, Waters Partner to Expand At-Home HPV Testing with Extended Genotyping

Quest Diagnostics and Waters Corp will expand at-home HPV screening nationwide in 2027, offering extended genotyping via the FDA-cleared Onclarity Self-Collection Kit through clinical, health plan, and consumer channels.

Cancer

New AI Tools Aim to Identify Tissue Samples at Risk of Failed Molecular Testing

Aignostics has launched HETA Clinical, an AI-based suite for digital pathology that analyzes whole-slide H&E images to assess tumor content and tissue quality, aiming to reduce molecular test failure rates in clinical labs.

Multi-Omics Blood Test Shows Promise for Early Detection of Three Gynecologic Cancers

Oct 9, 2026 | Cervical (HPV), Womens Health

New data show high diagnostic performance for ovarian, endometrial, and cervical cancers, with a targeted assay designed to run on existing clinical laboratory equipment.

Multi-Omic Test Predicts Radiation Therapy Benefit in Early-Stage Breast Cancer, Study Finds

Oct 9, 2026 | Breast

An independent validation study of 426 patients evaluated the assay’s ability to assess 10-year recurrence risk and identify patients more likely to benefit from radiation therapy.

10x Genomics, Fred Hutch Launch Cancer Diagnostics Research Collaboration

Oct 7, 2026 | Cancer, Leukemia, Molecular Diagnostics

10x Genomics and Fred Hutchinson Cancer Center have launched a multi-project collaboration to study single cell and spatial profiling for cancer diagnostics, including biomarkers in bladder cancer and residual disease detection in AML.

Cerenome Launches Two CSF Molecular Profiling Tests for CNS Cancers

Oct 7, 2026 | Cancer, Molecular Diagnostics

Cerenome has launched two CSF-based molecular profiling tests for CNS cancers, offering DNA and RNA sequencing panels to evaluate primary, metastatic, and hematologic malignancies in the central nervous system.

Pillar Biosciences Launches 80-Gene NGS Panel for Myeloid Malignancies

Oct 6, 2026 | Cancer, Molecular Diagnostics

Pillar Biosciences has introduced the oncoReveal Myeloid v2 Panel, expanding its NGS assay from 58 to 80 genes and enhancing FLT3-ITD detection while maintaining existing laboratory workflows.

Haystack MRD Accurately Predicts Colorectal Cancer Recurrence, Study Finds

Oct 5, 2026 | Colorectal

A study found that Quest Diagnostics’ Haystack MRD ctDNA test detected colorectal cancer recurrence with up to 100% specificity, outperforming CEA testing in DYNAMIC trial patient specimens.

Urine Cell-Free RNA Test Detects Bladder Cancer and Predicts Therapy Response

Oct 5, 2026 | Cancer, Urine Analyzers

A Stanford-led study found that Resero Bio’s uRARE-seq urine cfRNA test can non-invasively detect bladder cancer, assess tumor grade, and predict therapy response in 683 patient samples.

MIT Engineers Develop Handheld Device to Collect Viable Cells for Early Cancer Detection

Oct 1, 2026 | Anatomic Pathology, Cancer, Lab Equipment

Using microfluidic shear stress, the system detaches living cells from excised tissue to support pathology workflows and downstream diagnostic testing.

Astrin Biosciences Expands Access to Certitude Breast Cancer Blood Test to 48 States

Oct 1, 2026 | Breast

Astrin Biosciences has expanded access to its Certitude breast cancer blood test to 48 states through OpenLoop Health. The assay showed 92% sensitivity and 93% specificity in clinical validation.

Project HOPE Launches Wisconsin Initiative to Expand Prostate Cancer Screening

Oct 1, 2026 | Prostate

Project HOPE, funded by The Labcorp Charitable Foundation, has launched a two-year Madison, Wisconsin, initiative with local clinics to expand PSA testing and prostate cancer care for uninsured men facing access barriers.

Abbott Launches SimpleScreen CRC Blood Test for Colorectal Cancer Screening

Sep 30, 2026 | Colorectal

Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in average-risk adults, reporting 81.1% sensitivity and 90.4% specificity in a 48,000-patient study.

Decipher Prostate Test Predicts Benefit from Hormone Therapy in Phase III Trial

Sep 29, 2026 | Prostate

An ancillary analysis of the phase III NRG/RTOG 0815 trial shows Veracyte’s Decipher Prostate test can predict which intermediate-risk prostate cancer patients benefit from adding hormone therapy to radiation.

FDA Advisory Panel Backs Approval of GRAIL’s Galleri Multi-Cancer Early Detection Test

Sep 25, 2026 | Cancer, Compliance, Molecular Diagnostics

An FDA advisory panel voted 7-2 that the benefits of GRAIL’s Galleri multi-cancer early detection blood test outweigh its risks for adults 50 and older, supporting its premarket approval application.

Lucid Diagnostics Secures Favorable Medicare, CPT, and ICD-10 Recommendations for Esophageal Cancer Tests

Sep 22, 2026 | Cancer, Company News, Compliance

Lucid Diagnostics reports new Medicare, CPT, and ICD-10 panel recommendations supporting reimbursement and coding for its EsoGuard and EsoCheck esophageal cancer tests, advancing billing and clinical tracking pathways.

Electronic Genome Mapping Matches Cytogenetic Findings in Leukemia Proof-of-Principle Study

Sep 18, 2026 | Leukemia

A study led by Augusta University found 100% concordance between Nabsys OhmX electronic genome mapping and standard cytogenetic methods in detecting pathogenic variants in AML and CML bone marrow samples.